ENFN vs. DCBO, OPRA, FSLY, PDFS, BASE, VTEX, TUYA, EVBG, ZUO, and MOMO
Should you be buying Enfusion stock or one of its competitors? The main competitors of Enfusion include Docebo (DCBO), Opera (OPRA), Fastly (FSLY), PDF Solutions (PDFS), Couchbase (BASE), VTEX (VTEX), Tuya (TUYA), Everbridge (EVBG), Zuora (ZUO), and Hello Group (MOMO). These companies are all part of the "prepackaged software" industry.
Enfusion (NYSE:ENFN) and Docebo (NASDAQ:DCBO) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking.
Enfusion has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Docebo has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.
81.1% of Enfusion shares are owned by institutional investors. Comparatively, 53.2% of Docebo shares are owned by institutional investors. 39.2% of Enfusion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Docebo had 19 more articles in the media than Enfusion. MarketBeat recorded 23 mentions for Docebo and 4 mentions for Enfusion. Enfusion's average media sentiment score of 0.45 beat Docebo's score of -0.34 indicating that Enfusion is being referred to more favorably in the media.
Enfusion currently has a consensus price target of $9.33, indicating a potential downside of 3.48%. Docebo has a consensus price target of $55.00, indicating a potential upside of 47.61%. Given Docebo's stronger consensus rating and higher probable upside, analysts clearly believe Docebo is more favorable than Enfusion.
Docebo has a net margin of 3.55% compared to Enfusion's net margin of 1.40%. Docebo's return on equity of 19.31% beat Enfusion's return on equity.
Enfusion has higher earnings, but lower revenue than Docebo. Docebo is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Docebo received 43 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 66.67% of users gave Docebo an outperform vote while only 18.75% of users gave Enfusion an outperform vote.
Summary
Docebo beats Enfusion on 12 of the 18 factors compared between the two stocks.
Get Enfusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENFN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENFN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enfusion Competitors List
Related Companies and Tools
